{"name":"Bausch Health Americas, Inc.","slug":"bausch-health-americas-inc","ticker":"","exchange":"","domain":"bauschhealthamericas.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"immunology","drugs":[{"name":"Adapalene/Benzoyl Peroxide Facial Gel","genericName":"Adapalene/Benzoyl Peroxide Facial Gel","slug":"adapalene-benzoyl-peroxide-facial-gel","indication":"Acne vulgaris","status":"marketed"},{"name":"Dapsone plus Tretinoin Gel","genericName":"Dapsone plus Tretinoin Gel","slug":"dapsone-plus-tretinoin-gel","indication":"Acne vulgaris","status":"marketed"},{"name":"IDP-121 Vehicle Lotion","genericName":"IDP-121 Vehicle Lotion","slug":"idp-121-vehicle-lotion","indication":"Dermatological conditions (specific indication dependent on active ingredient formulated in vehicle)","status":"phase_3"},{"name":"IDP-122 Vehicle Lotion","genericName":"IDP-122 Vehicle Lotion","slug":"idp-122-vehicle-lotion","indication":"Dermatological condition (specific indication not publicly disclosed)","status":"phase_3"},{"name":"IDP-123 Vehicle Lotion","genericName":"IDP-123 Vehicle Lotion","slug":"idp-123-vehicle-lotion","indication":"Vehicle formulation for topical dermatological applications (specific indication dependent on active ingredient)","status":"phase_3"},{"name":"Adapalene Gel","genericName":"Adapalene Gel","slug":"adapalene-gel","indication":"Acne vulgaris","status":"marketed"},{"name":"Epiduo® Forte Gel","genericName":"Epiduo® Forte Gel","slug":"epiduo-forte-gel","indication":"Acne vulgaris","status":"phase_3"},{"name":"IDP 121 Lotion","genericName":"IDP 121 Lotion","slug":"idp-121-lotion","indication":"Atopic dermatitis","status":"phase_3"},{"name":"IDP-118 Vehicle Lotion","genericName":"IDP-118 Vehicle Lotion","slug":"idp-118-vehicle-lotion","indication":"Dermatological conditions (specific indication under Phase 3 investigation)","status":"phase_3"},{"name":"IDP-120 Gel","genericName":"IDP-120 Gel","slug":"idp-120-gel","indication":"Acne vulgaris","status":"phase_3"},{"name":"IDP-123 Lotion","genericName":"IDP-123 Lotion","slug":"idp-123-lotion","indication":"Inflammatory skin conditions (specific indication pending Phase 3 completion)","status":"phase_3"},{"name":"IDP-124 Vehicle Lotion","genericName":"IDP-124 Vehicle Lotion","slug":"idp-124-vehicle-lotion","indication":"Dermatological conditions requiring topical treatment (specific indication not publicly disclosed)","status":"phase_3"},{"name":"IDP-126 Vehicle Gel","genericName":"IDP-126 Vehicle Gel","slug":"idp-126-vehicle-gel","indication":"Dermatological conditions (specific indication not publicly disclosed)","status":"phase_3"},{"name":"IDp-120 Vehicle Gel","genericName":"IDp-120 Vehicle Gel","slug":"idp-120-vehicle-gel","indication":"Dermatological conditions (specific indication under investigation in Phase 3)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"neuroscience","drugs":[{"name":"IDP-122 Lotion","genericName":"IDP-122 Lotion","slug":"idp-122-lotion","indication":"Other","status":"marketed"},{"name":"Matching placebo rectal foam","genericName":"Matching placebo rectal foam","slug":"matching-placebo-rectal-foam","indication":"Other","status":"marketed"},{"name":"Tazorac Cream","genericName":"Tazorac Cream","slug":"tazorac-cream","indication":"Other","status":"marketed"},{"name":"Tretinoin Facial Gel","genericName":"Tretinoin Facial Gel","slug":"tretinoin-facial-gel","indication":"Other","status":"marketed"},{"name":"Viramidine","genericName":"Viramidine","slug":"viramidine","indication":"Other","status":"discontinued"},{"name":"Cimetidine IV","genericName":"Cimetidine IV","slug":"cimetidine-iv","indication":"Peptic ulcer disease","status":"phase_3"},{"name":"IDP-118 Monad Taz Lotion","genericName":"IDP-118 Monad Taz Lotion","slug":"idp-118-monad-taz-lotion","indication":"Other","status":"phase_2"},{"name":"Luliconazole Cream 1%","genericName":"Luliconazole Cream 1%","slug":"luliconazole-cream-1","indication":"Tinea pedis (athlete's foot)","status":"marketed"},{"name":"Neuromultivit","genericName":"Neuromultivit","slug":"neuromultivit","indication":"Other","status":"phase_3"},{"name":"Poly-L-Lactic Acid","genericName":"Poly-L-Lactic Acid","slug":"poly-l-lactic-acid","indication":"Other","status":"marketed"},{"name":"Sirdalud","genericName":"Sirdalud","slug":"sirdalud","indication":"Other","status":"phase_3"},{"name":"benzoyl peroxide wash","genericName":"benzoyl peroxide wash","slug":"benzoyl-peroxide-wash","indication":"Other","status":"marketed"},{"name":"double-blind rifaximin","genericName":"double-blind rifaximin","slug":"double-blind-rifaximin","indication":"Treatment of irritable bowel syndrome with diarrhea (IBS-D)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"High dose budesonide rectal foam","genericName":"High dose budesonide rectal foam","slug":"high-dose-budesonide-rectal-foam","indication":"Ulcerative colitis (distal/left-sided disease)","status":"marketed"},{"name":"IDP-124 Lotion","genericName":"IDP-124 Lotion","slug":"idp-124-lotion","indication":"Plaque psoriasis","status":"phase_3"},{"name":"IDP-126 Gel","genericName":"IDP-126 Gel","slug":"idp-126-gel","indication":"Plaque psoriasis","status":"phase_3"},{"name":"Granulated mesalamine","genericName":"Granulated mesalamine","slug":"granulated-mesalamine","indication":"Ulcerative colitis (induction and maintenance of remission)","status":"phase_3"},{"name":"IDP-118 Lotion","genericName":"IDP-118 Lotion","slug":"idp-118-lotion","indication":"Atopic dermatitis","status":"marketed"},{"name":"Low dose budesonide rectal foam","genericName":"Low dose budesonide rectal foam","slug":"low-dose-budesonide-rectal-foam","indication":"Ulcerative colitis (distal/left-sided disease)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Rifaximin SSD","genericName":"Rifaximin SSD","slug":"rifaximin-ssd","indication":"Traveler's diarrhea (approved indication for rifaximin)","status":"phase_3"},{"name":"ACYC vehicle","genericName":"ACYC vehicle","slug":"acyc-vehicle","indication":"Herpes simplex virus infections (topical indication, likely cold sores or genital herpes)","status":"phase_3"},{"name":"Low Dose Rifaximin DER","genericName":"Low Dose Rifaximin DER","slug":"low-dose-rifaximin-der","indication":"Treatment of hepatic encephalopathy","status":"phase_2"},{"name":"open-label rifaximin","genericName":"open-label rifaximin","slug":"open-label-rifaximin","indication":"Hepatic encephalopathy","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"respiratory","drugs":[{"name":"Methylnaltrexone (MNTX)","genericName":"Methylnaltrexone (MNTX)","slug":"methylnaltrexone-mntx","indication":"Opioid-induced constipation in patients with chronic non-cancer pain","status":"marketed"},{"name":"Methylnaltrexone (MOA-728)","genericName":"Methylnaltrexone (MOA-728)","slug":"methylnaltrexone-moa-728","indication":"Opioid-induced constipation in patients with chronic non-cancer pain","status":"phase_3"},{"name":"SC Methylnaltrexone (MNTX)","genericName":"SC Methylnaltrexone (MNTX)","slug":"sc-methylnaltrexone-mntx","indication":"Opioid-induced constipation in patients with chronic non-cancer pain","status":"phase_3"},{"name":"Tretinoin gel","genericName":"Tretinoin gel","slug":"tretinoin-gel","indication":"Acne vulgaris","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"rare","drugs":[{"name":"SC Methylnaltrexone","genericName":"SC Methylnaltrexone","slug":"sc-methylnaltrexone","indication":"Treatment of opioid-induced constipation in adult patients with advanced illness who have not responded to maximum doses of naloxegol or have a medical contraindication to naloxegol","status":"phase_3"},{"name":"tramadol HCl ER; celecoxib","genericName":"tramadol HCl ER; celecoxib","slug":"tramadol-hcl-er-celecoxib","indication":"Moderate to moderately severe chronic pain (Phase 3 indication)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Retigabine","genericName":"Retigabine","slug":"retigabine","indication":"Partial Epilepsy Treatment Adjunct","status":"discontinued"}]}],"pipeline":[{"name":"Rifaximin SSD","genericName":"Rifaximin SSD","slug":"rifaximin-ssd","phase":"phase_3","mechanism":"Rifaximin SSD is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.","indications":["Traveler's diarrhea (approved indication for rifaximin)","Hepatic encephalopathy (approved indication for rifaximin)","Irritable bowel syndrome with diarrhea (IBS-D) — Phase 3 pipeline indication"],"catalyst":""},{"name":"Adapalene/Benzoyl Peroxide Facial Gel","genericName":"Adapalene/Benzoyl Peroxide Facial Gel","slug":"adapalene-benzoyl-peroxide-facial-gel","phase":"marketed","mechanism":"Adapalene is a retinoid that normalizes skin cell turnover and reduces inflammation, while benzoyl peroxide kills acne-causing bacteria and provides additional antimicrobial activity.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Dapsone plus Tretinoin Gel","genericName":"Dapsone plus Tretinoin Gel","slug":"dapsone-plus-tretinoin-gel","phase":"marketed","mechanism":"Dapsone reduces inflammation and bacterial growth while tretinoin promotes skin cell turnover and normalizes keratinization to treat acne and related inflammatory skin conditions.","indications":["Acne vulgaris"],"catalyst":""},{"name":"High dose budesonide rectal foam","genericName":"High dose budesonide rectal foam","slug":"high-dose-budesonide-rectal-foam","phase":"marketed","mechanism":"Budesonide is a corticosteroid that suppresses local inflammation in the colon and rectum by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Ulcerative colitis (distal/left-sided disease)","Proctitis","Proctosigmoiditis"],"catalyst":""},{"name":"IDP-121 Vehicle Lotion","genericName":"IDP-121 Vehicle Lotion","slug":"idp-121-vehicle-lotion","phase":"phase_3","mechanism":"IDP-121 is a topical lotion vehicle formulation designed to deliver active pharmaceutical ingredients to the skin for localized therapeutic effect.","indications":["Dermatological conditions (specific indication dependent on active ingredient formulated in vehicle)"],"catalyst":""},{"name":"IDP-122 Lotion","genericName":"IDP-122 Lotion","slug":"idp-122-lotion","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IDP-122 Vehicle Lotion","genericName":"IDP-122 Vehicle Lotion","slug":"idp-122-vehicle-lotion","phase":"phase_3","mechanism":"IDP-122 is a topical lotion vehicle formulation designed to deliver active pharmaceutical ingredients to the skin for localized therapeutic effect.","indications":["Dermatological condition (specific indication not publicly disclosed)"],"catalyst":""},{"name":"IDP-123 Vehicle Lotion","genericName":"IDP-123 Vehicle Lotion","slug":"idp-123-vehicle-lotion","phase":"phase_3","mechanism":"IDP-123 is a topical lotion vehicle formulation designed to deliver active pharmaceutical ingredients through the skin for localized or systemic therapeutic effect.","indications":["Vehicle formulation for topical dermatological applications (specific indication dependent on active ingredient)"],"catalyst":""},{"name":"IDP-124 Lotion","genericName":"IDP-124 Lotion","slug":"idp-124-lotion","phase":"phase_3","mechanism":"IDP-124 is a topical lotion formulation combining calcipotriene and betamethasone dipropionate to reduce inflammation and normalize skin cell differentiation in psoriasis.","indications":["Plaque psoriasis"],"catalyst":""},{"name":"IDP-126 Gel","genericName":"IDP-126 Gel","slug":"idp-126-gel","phase":"phase_3","mechanism":"IDP-126 is a topical retinoid that modulates retinoid receptor signaling to reduce inflammation and promote skin cell differentiation in dermatological conditions.","indications":["Plaque psoriasis","Atopic dermatitis"],"catalyst":""},{"name":"Matching placebo rectal foam","genericName":"Matching placebo rectal foam","slug":"matching-placebo-rectal-foam","phase":"marketed","mechanism":"A placebo rectal foam formulation used as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Retigabine","genericName":"Retigabine","slug":"retigabine","phase":"discontinued","mechanism":"Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3, Potassium voltage-gated channel subfamily KQT member 4","indications":["Partial Epilepsy Treatment Adjunct"],"catalyst":""},{"name":"Tazorac Cream","genericName":"Tazorac Cream","slug":"tazorac-cream","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tretinoin Facial Gel","genericName":"Tretinoin Facial Gel","slug":"tretinoin-facial-gel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Viramidine","genericName":"Viramidine","slug":"viramidine","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACYC vehicle","genericName":"ACYC vehicle","slug":"acyc-vehicle","phase":"phase_3","mechanism":"ACYC vehicle is a topical formulation designed to enhance the delivery and efficacy of acyclovir for localized antiviral treatment.","indications":["Herpes simplex virus infections (topical indication, likely cold sores or genital herpes)"],"catalyst":""},{"name":"Adapalene Gel","genericName":"Adapalene Gel","slug":"adapalene-gel","phase":"marketed","mechanism":"Adapalene is a third-generation retinoid that binds to retinoic acid receptors to normalize skin cell differentiation and reduce inflammation.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Cimetidine IV","genericName":"Cimetidine IV","slug":"cimetidine-iv","phase":"phase_3","mechanism":"Cimetidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells.","indications":["Peptic ulcer disease","Gastroesophageal reflux disease (GERD)","Zollinger-Ellison syndrome","Acute upper gastrointestinal bleeding prophylaxis"],"catalyst":""},{"name":"Epiduo® Forte Gel","genericName":"Epiduo® Forte Gel","slug":"epiduo-forte-gel","phase":"phase_3","mechanism":"Epiduo Forte combines adapalene (a retinoid) and benzoyl peroxide to reduce acne by normalizing skin cell turnover and killing acne-causing bacteria.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Granulated mesalamine","genericName":"Granulated mesalamine","slug":"granulated-mesalamine","phase":"phase_3","mechanism":"Mesalamine is an anti-inflammatory agent that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene production.","indications":["Ulcerative colitis (induction and maintenance of remission)","Crohn's disease (colonic involvement)"],"catalyst":""},{"name":"IDP 121 Lotion","genericName":"IDP 121 Lotion","slug":"idp-121-lotion","phase":"phase_3","mechanism":"IDP 121 is a topical lotion formulation designed to treat inflammatory skin conditions by reducing inflammation and modulating immune response in the skin.","indications":["Atopic dermatitis","Other inflammatory skin conditions"],"catalyst":""},{"name":"IDP-118 Lotion","genericName":"IDP-118 Lotion","slug":"idp-118-lotion","phase":"marketed","mechanism":"IDP-118 Lotion is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.","indications":["Atopic dermatitis","Plaque psoriasis","Other inflammatory dermatoses"],"catalyst":""},{"name":"IDP-118 Monad Taz Lotion","genericName":"IDP-118 Monad Taz Lotion","slug":"idp-118-monad-taz-lotion","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IDP-118 Vehicle Lotion","genericName":"IDP-118 Vehicle Lotion","slug":"idp-118-vehicle-lotion","phase":"phase_3","mechanism":"IDP-118 is a topical lotion vehicle formulation designed to deliver active pharmaceutical ingredients to the skin for localized therapeutic effect.","indications":["Dermatological conditions (specific indication under Phase 3 investigation)"],"catalyst":""},{"name":"IDP-120 Gel","genericName":"IDP-120 Gel","slug":"idp-120-gel","phase":"phase_3","mechanism":"IDP-120 Gel is a topical retinoid formulation designed to treat acne and other skin conditions by promoting cell turnover and reducing sebum production.","indications":["Acne vulgaris"],"catalyst":""},{"name":"IDP-123 Lotion","genericName":"IDP-123 Lotion","slug":"idp-123-lotion","phase":"phase_3","mechanism":"IDP-123 is a topical lotion formulation designed to treat inflammatory skin conditions by modulating local immune and inflammatory pathways.","indications":["Inflammatory skin conditions (specific indication pending Phase 3 completion)"],"catalyst":""},{"name":"IDP-124 Vehicle Lotion","genericName":"IDP-124 Vehicle Lotion","slug":"idp-124-vehicle-lotion","phase":"phase_3","mechanism":"IDP-124 is a topical lotion vehicle formulation designed to deliver active pharmaceutical ingredients to the skin for localized therapeutic effect.","indications":["Dermatological conditions requiring topical treatment (specific indication not publicly disclosed)"],"catalyst":""},{"name":"IDP-126 Vehicle Gel","genericName":"IDP-126 Vehicle Gel","slug":"idp-126-vehicle-gel","phase":"phase_3","mechanism":"IDP-126 is a topical gel formulation designed to deliver active pharmaceutical ingredients to treat dermatological conditions.","indications":["Dermatological conditions (specific indication not publicly disclosed)"],"catalyst":""},{"name":"IDp-120 Vehicle Gel","genericName":"IDp-120 Vehicle Gel","slug":"idp-120-vehicle-gel","phase":"phase_3","mechanism":"IDp-120 is a topical immunomodulatory gel formulation designed to enhance local immune response at the application site.","indications":["Dermatological conditions (specific indication under investigation in Phase 3)"],"catalyst":""},{"name":"Low Dose Rifaximin DER","genericName":"Low Dose Rifaximin DER","slug":"low-dose-rifaximin-der","phase":"phase_2","mechanism":"Inhibits bacterial RNA synthesis","indications":["Treatment of hepatic encephalopathy"],"catalyst":""},{"name":"Low dose budesonide rectal foam","genericName":"Low dose budesonide rectal foam","slug":"low-dose-budesonide-rectal-foam","phase":"marketed","mechanism":"Budesonide is a corticosteroid that suppresses local inflammation in the colon and rectum by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Ulcerative colitis (distal/left-sided disease)","Mild to moderate active ulcerative colitis"],"catalyst":""},{"name":"Luliconazole Cream 1%","genericName":"Luliconazole Cream 1%","slug":"luliconazole-cream-1","phase":"marketed","mechanism":"Luliconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Tinea pedis (athlete's foot)","Tinea cruris (jock itch)","Tinea corporis (ringworm)"],"catalyst":""},{"name":"Methylnaltrexone (MNTX)","genericName":"Methylnaltrexone (MNTX)","slug":"methylnaltrexone-mntx","phase":"marketed","mechanism":"Methylnaltrexone is a peripheral mu-opioid receptor antagonist that blocks opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation.","indications":["Opioid-induced constipation in patients with chronic non-cancer pain","Opioid-induced constipation in patients with advanced illness receiving palliative care"],"catalyst":""},{"name":"Methylnaltrexone (MOA-728)","genericName":"Methylnaltrexone (MOA-728)","slug":"methylnaltrexone-moa-728","phase":"phase_3","mechanism":"Methylnaltrexone is a peripheral mu-opioid receptor antagonist that blocks opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation while preserving central analgesia.","indications":["Opioid-induced constipation in patients with chronic non-cancer pain","Opioid-induced constipation in patients with advanced illness receiving palliative care"],"catalyst":""},{"name":"Neuromultivit","genericName":"Neuromultivit","slug":"neuromultivit","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Poly-L-Lactic Acid","genericName":"Poly-L-Lactic Acid","slug":"poly-l-lactic-acid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SC Methylnaltrexone","genericName":"SC Methylnaltrexone","slug":"sc-methylnaltrexone","phase":"phase_3","mechanism":"SC Methylnaltrexone is a peripherally acting mu-opioid receptor antagonist that blocks the action of opioids in the gastrointestinal tract.","indications":["Treatment of opioid-induced constipation in adult patients with advanced illness who have not responded to maximum doses of naloxegol or have a medical contraindication to naloxegol"],"catalyst":""},{"name":"SC Methylnaltrexone (MNTX)","genericName":"SC Methylnaltrexone (MNTX)","slug":"sc-methylnaltrexone-mntx","phase":"phase_3","mechanism":"Methylnaltrexone is a peripheral mu-opioid receptor antagonist that blocks opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation.","indications":["Opioid-induced constipation in patients with chronic non-cancer pain","Opioid-induced constipation in patients with advanced illness receiving palliative care"],"catalyst":""},{"name":"Sirdalud","genericName":"Sirdalud","slug":"sirdalud","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tretinoin gel","genericName":"Tretinoin gel","slug":"tretinoin-gel","phase":"marketed","mechanism":"Tretinoin is a vitamin A derivative that binds to retinoic acid receptors in the nucleus, promoting cell differentiation and reducing sebum production and comedone formation.","indications":["Acne vulgaris","Photoaging and fine wrinkles","Acute promyelocytic leukemia (systemic formulation)"],"catalyst":""},{"name":"benzoyl peroxide wash","genericName":"benzoyl peroxide wash","slug":"benzoyl-peroxide-wash","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"double-blind rifaximin","genericName":"double-blind rifaximin","slug":"double-blind-rifaximin","phase":"phase_3","mechanism":"Rifaximin works by inhibiting bacterial RNA synthesis.","indications":["Treatment of irritable bowel syndrome with diarrhea (IBS-D)"],"catalyst":""},{"name":"open-label rifaximin","genericName":"open-label rifaximin","slug":"open-label-rifaximin","phase":"phase_3","mechanism":"Rifaximin works by inhibiting bacterial RNA synthesis, thereby reducing bacterial load in the gut.","indications":["Hepatic encephalopathy","Irritable bowel syndrome with diarrhea (IBS-D)"],"catalyst":""},{"name":"tramadol HCl ER; celecoxib","genericName":"tramadol HCl ER; celecoxib","slug":"tramadol-hcl-er-celecoxib","phase":"phase_3","mechanism":"This combination product uses tramadol (an opioid agonist and monoamine reuptake inhibitor) for pain relief and celecoxib (a selective COX-2 inhibitor) for anti-inflammatory effects.","indications":["Moderate to moderately severe chronic pain (Phase 3 indication)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPTWdkLXZqTVBOSkpkbFA0WHcyVzNqT0NVcTExN0ZsaDQxMnUxaHE2SDlRZUZ0UW04NWlhSkdCNDZWaEtoVzlrWnpGRi1hYUpQNzJlQnkyOUdXVlFEaDk2dlVfczVibXVHRXRaZTBERzdUMGl4MDBFVHZlNm1aTmQtck51aFdXYmlRdm5SOVFWdUJabjFwVnVpWGpWQnRldw?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Acne Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2032, estimates DelveInsight - openPR.com","headline":"Acne Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2032, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-24","type":"regulatory","source":"The Hindu","summary":"Alembic Pharma gets U.S. FDA nod for generic antifungal drug - The Hindu","headline":"Alembic Pharma gets U.S. FDA nod for generic antifungal drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPcDV6SGJVckFqcWZvTjcwaS1NTlR6eVNneDhHZ1JVNHRsN1ZPcUtMS3hPNTZtM2swWl8xTEdOUEJRcE9QcXFCcjhhRFNMYnljcF9nXzlkZkV0eW1raVZkdW5ycXdTMEE0ZktBZlV4emZxbktuaG81cnUtdzhOLWRnTG5hc2o1YnNTNlRqRzhnRWpuV2ZtUDRzZUlwZlYtMWhvT01JYm1YTFBFd2RXZ1JMNDlmbGlhUzZYSWpBRmFWeUFjeHItSnM4Qi1yVXlTcE1hZ3FLbmFwWmZJY2M?oc=5","date":"2026-02-11","type":"patent","source":"KTVB","summary":"Idaho joins $17.85M settlement over alleged generic drug price-fixing - KTVB","headline":"Idaho joins $17.85M settlement over alleged generic drug price-fixing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPM0I3cTl6d0VjazNnZFc0d213aUlncVUtdzY5TElBSlFHRS1PUEszaFNxMEZWb2ZnWU53M2FnMjhwMWR6QXFsbEdjMklNV1g4eXpYWnhLcXIzcmtRaHFBRUZ0NmFTeDF1QzY2cTVRU0JKUEVHUVM0c2RMSFdEYlZ4T05ySzRobHBjcEpUcFNn?oc=5","date":"2026-02-07","type":"pipeline","source":"lupin.com","summary":"Lupin launches Ethacrynic Acid Tablets USP - Lupin | Press Release - lupin.com","headline":"Lupin launches Ethacrynic Acid Tablets USP - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPOVNTbXRIVURaZUllbjJtMFFqWTBUMzdLUjZLeWZrNW5MLU1hdTQzZHU4aDdvX2RKT0lYdkxQQ3VidDhuU0xSVEtncWwzQXJ4djhUb1RBOHpCQVAwLVFJZEV2R0VtS1hLbnZLUXRxT1c0NE8tQU9fcjRZcjI4WVJBZnl4X0M4Rmo1d2V6eFBTNDRGZzhmMFV0a3VJbWdOM1BzUHg3LXU2SjFQQmc1YXRyOGFSVkwwTzB3Ymk2a2FMQjY5UFNyRnJvcXBaUXp2eFpUaDhzZ0cwZWdNblZUbkdjSVBseXFsU21wck51dA?oc=5","date":"2026-02-04","type":"pipeline","source":"fox61.com","summary":"Connecticut AG William Tong settles with Lannett and Bausch for nearly $18 million - fox61.com","headline":"Connecticut AG William Tong settles with Lannett and Bausch for nearly $18 million - fox61.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPUVlfZEVDaTZ1clBrSmJaLTZIRTI0VlQtd1RabXNJRkJZYkVMZjQ5SGdtOGhsRk9UZVFKMnFMTmdiNGNaUTdUUDUyd1BzTER2dkM4UUxueGNCZEJVb21GTDFWN3ZpdGZxTy01Z1pwMW53RloySFZvMHlwb3dJVmhveGxuVDlQUE5tS2psOFlXQ0dOVTNHNXRIZWNmelJtaGNhQU1MS1B1eF9YdXp2RE90dldHY25QSjBiQnBpeTVNdDhZLU5nc0dqNldRZnRob0hDWU5YUmI4WGdPU3JwelBpODNxcUpaRUs3MlZlWFZzcWtfazQ?oc=5","date":"2026-02-03","type":"patent","source":"NCDOJ (.gov)","summary":"Attorney General Jeff Jackson Reaches $17.85 Million Settlement with Lannett and Bausch Over Generic Drug Price Fixing; Sues Novartis and Sandoz - NCDOJ (.gov)","headline":"Attorney General Jeff Jackson Reaches $17.85 Million Settlement with Lannett and Bausch Over Generic Drug Price Fixing; ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5FcHpCV1V1cEJUTGFWVnRjNlNhenJfLWRBMU1lazlYY05FOVBEZDBlQ3hCRjlFZHNmc3VFZzN5ZW5sOWpvTF9NTll5WEJ2V0RQVTZWR20zM3daNGs4Q0dnX0NEZ2F2Q0lVOUc5ZjROQ2FVZjF3dG5ZZEtB?oc=5","date":"2026-02-03","type":"patent","source":"KTAR News 92.3 FM","summary":"Arizona AG announces settlements over generic drug prices - KTAR News 92.3 FM","headline":"Arizona AG announces settlements over generic drug prices - KTAR News 92.3 FM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNVG9zRnFxeVdtUmdtLVNEakluODU4RWdrZnRYS2hIN0hsckQzamVkRFhsSFRkblBuS0diQWpoaVRqdHhmUERQc21kalJyM3d3RklHU2NpSG9hZW5HbTU0Ti0zdjdINjBTb1liQWRoaFI5aGxLLXlhck4yd0QzdmZmU0s4Wkl4dw?oc=5","date":"2026-02-03","type":"pipeline","source":"The Business Journals","summary":"Massachusetts joins 42 states in suing pharma giant over price fixing scheme - The Business Journals","headline":"Massachusetts joins 42 states in suing pharma giant over price fixing scheme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxON05oMkJybUZma0tOLUFuSDB3YXJIcE94SjhxcXJTbXpteEtnUE43MmV0Y1ROVFA3UE9kSVNZc3I3STNxZE04U1BnQ0txS2FwT0JOb3lkckZKQWJjbl9WdmZ2S3d0eHBZVXJqYzhBeUJNT0dmVHNWc2xJcGNQRS13aTdkV1BjbnB1UGk0RERuZlZRQnNoVEk4cNIBVkFVX3lxTFB3NVJ0TmlhQWxJemdFcVhyZmt3RVJBNHhMQUFPeUhJRkxKYW1PaW9Uc0FQOXY0ZnlZSnl5SGF0TVZRZnlQRGNUQkNDX0RPelJqY2hzYnl3?oc=5","date":"2026-02-02","type":"deal","source":"Law360","summary":"Bausch, Lannett To Pay $17.9M In Drug Price-Fixing Deal - Law360","headline":"Bausch, Lannett To Pay $17.9M In Drug Price-Fixing Deal - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNdjNoVlh1LW1YT0tmLW5yQWE4YmZkT0FTZ3U3NHlaNF84ZDNzdmQ4cUZVQ1lPa1hsbmg2V21MZkg5QnNFNFA0dHhaQXFnZnJhQl85SlpsV1FMRUFrdXJCZEJ6dFk4Q2NfcW0tTzJ5b2gycjlIeTFwQzZDZUc0RjVpbDRDeTlrUTdvZWNfTWNUdzhDNjN1dEVYOUZ5WUtKdmFmOXRz?oc=5","date":"2026-02-02","type":"deal","source":"USA Herald","summary":"Lannett and Bausch Drug Price Fixing Deal Reaches $17.85M Multistate Settlement - USA Herald","headline":"Lannett and Bausch Drug Price Fixing Deal Reaches $17.85M Multistate Settlement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxONlBwei1YN0hlbWNhTEdhZGkweGNSaUhfZmc1d1BxYjdiejV4bjRLaTlIMDIwUEpWQWtOYzlNZzNxS1ZXZHVmMjYybWwwTFlYaWRnaTVpMGFuQ0xtc1h1cHdocExmZWRQRnZPT1Nnd2RCX09jRGhXb0RvZmVxaHhyNkZZQUttUjdDdHd1eHBjc21FQjVNSWU4dGxXLWp1SWNBS2VXTVQzUmhWSFJOSnh2OEhCVjRYOWxtLWlxYUxTeThXTDc5ZVRYeGxRTFdxd0ZCSjAwZ0g1WnBWSnV3UlpKajFkMlJIZEtvc29GZ1lmcDBkMXlYRjFUbk5IOVB0VjhmNEtnWmFqbWhpNEdGNVE?oc=5","date":"2025-08-12","type":"earnings","source":"PR Newswire","summary":"DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health - PR Newswire","headline":"DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch H","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNTUc2SHZsNGwyaURlQ0VzbXltMFZfcW9mbngyOG5wc3B4UzlSYm5tLWVveV9EZEZ4elhWd3NMQUxtV0hQa3g1ci16bXRkOW5zS2p5WGp4MlluODhESVNQc0lHZ1NKNEs5d1I1X19xZG9sU3J4WHZjbGduRkRvZndoSVotX0NIQ19PRk0wUmkwazB4Nl9XcEFCcXZJNkMwNE9sYzlocTdENlhsNDVyZUg3MUc2N3F2eVB6QTFhUFZjd01NQ2JNMWYySDVUMjc1Nmpic1M0dURVVlJiaHRwd3FseGhZZWtsSkFFVF9kQ1h1UVRRV2pHNEQ0dm1YejJUZ2NxTXI0dzBYYlVpTGpka0RzMEJmcEo0LXVYdU04?oc=5","date":"2025-07-29","type":"deal","source":"PR Newswire","summary":"Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease - PR Newswire","headline":"Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients wi","sentiment":"neutral"}],"patents":[],"drugCount":44,"phaseCounts":{"phase_3":25,"marketed":15,"discontinued":2,"phase_2":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}